Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Slides:

Advertisements

Similar presentations

Figure 3. TLT-6 expressions in hematopoietic stem cells, monocyts and macrophages. (A) Expression patterns of TLT-6 in the surface of hematopoietic lineage.

Advertisements

Synergistic antitumor effect of anti-CD40/CpG and 14

Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Resveratrol modulates DSS-induced neutrophils during colitis.

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

Attenuated MDSC-suppressive activity and metastasis development in IDO-deficient mice is rescued by IL-6. Attenuated MDSC-suppressive activity and metastasis.

Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

TANs mediate obesity-induced tumor progression and aggravated desmoplasia. TANs mediate obesity-induced tumor progression and aggravated desmoplasia. A,

Epithelial loss of TβRII results in increased Th17 cell development.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

Treatment of ob/ob mice with TTR-ASOs reduces adipose tissue inflammation. Treatment of ob/ob mice with TTR-ASOs reduces adipose tissue inflammation. A:

Diclofenac treatment reduces L-selectin on peripheral blood and infiltrated leukocytes but does not alter accumulation in the injured spinal cord. Diclofenac.

Volume 26, Issue 4, Pages (April 2018)

Shared phenotype of CD4+CLA+CD103+ T cells from human blood and skin.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

CT-26 colon cancer induces the recruitment of protumor mast cells and the accumulation of MDSCs. CT-26 colon carcinoma cells (2 × 105) were injected s.c.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

KIR-CARs/Dap12 trigger robust antigen-specific cytotoxicity in vitro.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

Vaginal CD11c+ DCs from IL-17A−/− mice are impaired in potentiating Th17 responses because of diminished IL-1β production. Vaginal CD11c+ DCs from IL-17A−/−

Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.

CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.

Treatment with R848 and anti-CD200R leads to changes in the composition of intratumor myeloid cells. Treatment with R848 and anti-CD200R leads to changes.

Kinetic of NFAT-CBR expression.

pDCs from the melanoma environment responded to TLR-L stimulation.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

Time to onset of hypothyroidism after first treatment with immune checkpoint inhibitors in the combination therapy and monotherapy groups. Time to onset.

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

5FU-induced specific activation of CD8+ T cells.

CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. CDN–treated MOC1 tumors demonstrate enhanced.

ALT-803 stimulates proliferation and activation of human NK cells and T cells in vitro. ALT-803 stimulates proliferation and activation of human NK cells.

IL8 and TNFα are required for neutrophil-induced UMSCC47 increase in invasion. IL8 and TNFα are required for neutrophil-induced UMSCC47 increase in invasion.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

PD-L1 is expressed in breast cancer.

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

CPI-444 enhances T-cell activation in MC38 tumors.

Trametinib and combination promote moDC maturation and decrease moDC viability. Trametinib and combination promote moDC maturation and decrease moDC viability.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways. In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

MDSC population in patient peripheral blood.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Phenotyping of T cells. Phenotyping of T cells. Circulating lymphocytes from a tumor-naïve C57BL/6 mice (left column) were compared with those from C57BL/6.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

Presentation transcript:

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Single-cell suspensions of CT26 tumors were analyzed by flow cytometry (24 hours after the therapy). Percentage of viable immune cells CD45.2+ (A) and nonimmune cells (B). C, Percentage of intratumoral myeloid cells (CD11b+). Expression of macrophage markers was analyzed in the CD11b+ cell population: (D) CD206, (E) CD86, (F) CD115, (G) F4/80, n = 8–9. H, Examples of expression of the F4/80, CD206, CD86, and CD115 in R848/anti-CD200R and control mice. I, Production of IL1β in intratumoral CD11b+ cell, upon stimulation with LPS, n = 8–9. J, Examples of IL1β expression in all treatment groups. A–H, Reproduced two times. I and J, Performed once. When not indicated otherwise, significance was calculated in comparison with the PBS-only control group using one-way ANOVA. *, P < 0.05; ** P < 0.01; ***, P < 0.001. Zofia Pilch et al. Cancer Immunol Res 2018;6:930-940 ©2018 by American Association for Cancer Research